Efficacy and Safety of a New Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, Atorvastatin, in Patients with Combined Hyperlipidemia: Comparison with Fenofibrate

This 24-week, randomized, open-label multicenter study evaluated the efficacy and safety of atorvastatin compared with fenofibrate in the treatment of patients with combined hyperlipidemia (CHL). Following a 6-week baseline period, 84 patients with CHL were randomly assigned to either atorvastatin t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arteriosclerosis, thrombosis, and vascular biology thrombosis, and vascular biology, 1997-09, Vol.17 (9), p.1793-1799
Hauptverfasser:	Ooi, Teik C, Heinonen, Therese, Alaupovic, Petar, Davignon, Jean, Leiter, Lawrence, Lupien, Paul J, Sniderman, Allan D, Tan, Meng H, Tremblay, Gerald, Sorisky, Alexander, Shurzinske, Linda, Black, Donald M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Atorvastatin Biological and medical sciences Diet Female Fenofibrate - adverse effects Fenofibrate - therapeutic use General and cellular metabolism. Vitamins Heptanoic Acids - adverse effects Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hyperlipidemias - drug therapy Hypolipidemic Agents - adverse effects Hypolipidemic Agents - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Pyrroles - adverse effects Pyrroles - therapeutic use Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!